CHICAGO — The American Medical Association (AMA) announced today that the current procedural terminology (CPT®) code set has been updated by the CPT editorial panel to include vaccine and dosing codes for pediatric doses of the COVID-19 vaccine developed by Pfizer.
The preliminary CPT codes will be in effect for use subject to approval of Pfizer’s two-dose regimen for the prevention of COVID-19 in children ages 5 to 11 or authorization for emergency use from the U.S. Food and Drug Administration ( FDA). The AMA is now publishing the CPT code update to ensure electronic systems in the U.S. healthcare system are prepared in advance for potential FDA approval or authorization.
“The AMA supports the goal of extending protection from COVID-19 vaccination to a wider age group of children,” said AMA president Gerald E. Harmon, MD. “A rigorous, transparent review process by the Federal Drug Administration and Centers for Disease Control and Prevention will examine the safety and efficacy of Pfizer’s COVID-19 vaccine for potential use in children ages 5-11.12.”
The development of vaccine-specific CPT codes has clinically differentiated every coronavirus vaccine and dosing schedule for better tracking, reporting and analysis that supports data-driven planning and allocation. COVID-19 vaccines from AstraZeneca, Janssen (Johnson & Johnson), Moderna, Novavax and Pfizer have previously received unique CPT codes.
To ensure accurate coding and reporting of COVID-19 vaccines and immunization services, the AMA provides a vaccine code finding tool to help identify the correct CPT code combination for the type and dose of COVID-19 vaccine given to each. patient is provided.
For quick reference, the new vaccine and administration codes assigned to the pediatric doses of Pfizer’s COVID-19 vaccine are:
Product code vaccine
91307 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative-free, 10 mcg/0.2 ml dose, reconstituted diluent, tris-sucrose formulation, for intramuscular use
Vaccine Administration Codes
0071A Administration of immunization by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative-free, 10 mcg/0.2 mL dose, reconstituted diluent, tris-sucrose formulation; first dose
0072A Administration of immunization by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative-free, 10 mcg/0.2 mL dose, reconstituted diluent, tris-sucrose formulation; second dose
Short, medium, and long descriptions for all new vaccine-specific CPT codes are accessible on the AMA website, along with other recent changes to the CPT code set that have helped streamline the public health response to the SARS-CoV-2 virus and the disease COVID-19.
Changes to the CPT code set are considered through an open editorial process managed by the CPT editorial panel that gathers broad input from the healthcare community and beyond to ensure that the CPT content meets the coding requirements of digital health, precision medicine, augmented intelligence, and others. reflects aspects of a modern healthcare system. This rigorous editorial process keeps the CPT Code current with today’s medical science and technology so that it can fulfill its vital role as the trusted language of medicine today and the code for its future.
# # #
Questions about CPT encryption and content should be directed to the CPT Network, the authoritative source for answers to CPT encryption. Also refer to the AMA online library of COVID-19 CPT Coding and Guidance.